{
  "schema_version": 1,
  "generated_at": "2026-05-20T10:39:12Z",
  "ticker": "VRTX",
  "headlines": [
    {
      "title": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It",
      "publisher": "Zacks",
      "published_at": "2026-05-19T13:00:05+00:00",
      "age_hours": 21.65199383527778,
      "link": "https://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-incorporated-vrtx-trending-130005659.html",
      "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store."
    },
    {
      "title": "CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms",
      "publisher": "MarketBeat",
      "published_at": "2026-05-16T00:12:19+00:00",
      "age_hours": 106.44810494944446,
      "link": "https://www.marketbeat.com/instant-alerts/crispr-therapeutics-enters-second-phase-as-casgevy-momentum-builds-pipeline-data-looms-2026-05-15/?utm_source=yahoofinance&utm_medium=yahoofinance",
      "summary": "CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a \u201csecond phase\u201d as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host"
    },
    {
      "title": "5 Must-Read Analyst Questions From Vertex Pharmaceuticals\u2019s Q1 Earnings Call",
      "publisher": "StockStory",
      "published_at": "2026-05-13T23:40:55+00:00",
      "age_hours": 154.97143828472224,
      "link": "https://finance.yahoo.com/markets/stocks/articles/5-must-read-analyst-questions-234055279.html",
      "summary": "Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management highlighting commercial momentum in both established and emerging product areas. CEO Reshma Kewalramani pointed to \"strong revenue growth as we reach more patients with more products,\" emphasizing milestone achievements for AlifTrack, KASJEVY, and Gernavix. The company also attributed performance to broader label eligibility and successful int"
    },
    {
      "title": "Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley",
      "publisher": "MT Newswires",
      "published_at": "2026-05-12T15:54:17+00:00",
      "age_hours": 186.7486605086111,
      "link": "https://finance.yahoo.com/markets/stocks/articles/halozyme-q1-beat-driven-royalty-155417165.html",
      "summary": "Halozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensu"
    },
    {
      "title": "Vertex\u2019s Germany CASGEVY Deal Highlights Growing Non CF Growth Story",
      "publisher": "Simply Wall St.",
      "published_at": "2026-05-12T13:20:27+00:00",
      "age_hours": 189.31254939944444,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/vertex-germany-casgevy-deal-highlights-132027635.html",
      "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed Germany's first sustainable access deal for CASGEVY, a gene therapy for severe sickle cell disease and transfusion dependent beta thalassemia. The agreement with GKV-Spitzenverband aims to secure long term, reimbursed access to this one time treatment for eligible patients across the German statutory health system. This adds to Vertex's broader reimbursement progress for CASGEVY in multiple countries, expanding global reach beyond its..."
    }
  ]
}